Evolving concepts in Phase I and II Drug Development for Crohn's Disease.

Evolving concepts in Phase I and II Drug Development for Crohn's Disease.

The highest attrition rates during drug development programs occur at the proof of concept stage. Given the large number of molecules under development for Crohn's disease, a need exists to improve the efficiency of early drug development by fast-tracking promising agents and terminating ineffe...

Descrición completa

Detalles Bibliográficos
Main Authors:	Jairath, V, Levesque, B, Vande Casteele, N, Khanna, R, Mosli, M, Hindryckx, P, Travis, S, Duijvenstein, M, Rimola, J, Panes, J, D'Haens, G, Sandborn, W, Feagan, B
Formato:	Journal article
Idioma:	English
Publicado:	Oxford University Press 2016

Títulos similares

Evolving concepts in phases I and II drug development for Crohn's Disease
por: Jairath, V, et al.
Publicado: (2016)

The Crohn's disease–ulcerative colitis clinical appraisal update: emerging trends in clinical practice
por: Sandborn, W, et al.
Publicado: (2016)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for Crohn's disease
por: Jairath, V, et al.
Publicado: (2016)

Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease.
por: D'Haens, G, et al.
Publicado: (2009)

Biosimilars in IBD: hope or expectation?
por: Gecse, K, et al.
Publicado: (2013)

Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process.
por: Peyrin-Biroulet, L, et al.
Publicado: (2012)

Development of red flags index for early referral of adults with symptoms and signs suggestive of Crohn’s disease: an IOIBD initiative
por: Danese, S, et al.
Publicado: (2015)

Development of the Crohn's disease digestive damage score, the Lemann score.
por: Pariente, B, et al.
Publicado: (2011)

Standardizing scoring conventions for Crohn’s disease endoscopy: An international RAND/UCLA appropriateness study
por: Khanna, R, et al.
Publicado: (2023)

Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis
por: Samaan, MA, et al.
Publicado: (2018)

Biologic Therapies: From Complexity to Clinical Practice in a Changing Environment
por: Remo Panaccione, et al.
Publicado: (2015-12-01)

Biomarker correlation with endoscopic outcomes in patients with Crohn's disease: data from CALM
por: Reinisch, W, et al.
Publicado: (2018)

Systematic review and meta-analysis: Prevalence, risk factors, and costs of aminosalicylate use in Crohn’s disease
por: Ma, C, et al.
Publicado: (2018)

Placebo response and remission rates in Ulcerative Colitis clinical trials: Systematic review and meta-analysis
por: Jairath, V, et al.
Publicado: (2015)

A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998.
por: Gasche, C, et al.
Publicado: (2000)

Central Endoscopy Reading in Inflammatory Bowel Diseases
por: Panés, J, et al.
Publicado: (2016)

Characterization of Mucosal Lesions in Crohn's Disease Scored With Capsule Endoscopy: A Systematic Review
por: Miquel Marquès Camí, et al.
Publicado: (2021-01-01)

Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis
por: Jairath, V, et al.
Publicado: (2017)

Steroid-Dependent Crohn’s Disease
por: William J Sandborn
Publicado: (2000-01-01)

Infliximab in the Treatment of Crohn’s Disease
por: Brian Feagan
Publicado: (2000-01-01)

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.
por: Van Assche, G, et al.
Publicado: (2011)

Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn’s disease
por: Ariela K. Holmer, et al.
Publicado: (2020-11-01)

A product review of vedolizumab in inflammatory bowel disease
por: Robert Battat, et al.
Publicado: (2019-10-01)

“Dramatische taalvaardigheid” and how to remediate it - Developing and evaluating a remedial writing programme in a Dutch-medium secondary school
por: D'Haens, A
Publicado: (2020)

Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
por: Sandborn, W, et al.
Publicado: (2015)

Differentiation of fibrotic and inflammatory component of Crohn’s disease-associated strictures
por: Jordi Rimola, et al.
Publicado: (2020-04-01)

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
por: Colombel, J, et al.
Publicado: (2017)

Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials.
por: Gottlieb, K, et al.
Publicado: (2015)

Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial
por: Panaccione, R, et al.
Publicado: (2019)

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.
por: Travis, S, et al.
Publicado: (2006)

Linguistic strategies referring to politicians in the Spanish written press: an analysis of appositive constructions
por: An Vande Casteele
Publicado: (2010-12-01)

Linguistic strategies referring to politicians in the Spanish written press: an analysis of appositive constructions
por: An Vande Casteele
Publicado: (2011-04-01)

The missing “C”: Crohn's, colitis and coping
por: Turki AlAmeel, et al.
Publicado: (2019-01-01)

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis
por: Travis, S, et al.
Publicado: (2013)

Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study.
por: Travis, S, et al.
Publicado: (2014)

Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohn’s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial)
por: Vipul Jairath, et al.
Publicado: (2022-04-01)

Budesonide MMX® for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis.
por: Lichtenstein, G, et al.
Publicado: (2015)

Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitis
por: Bryan Linggi, et al.
Publicado: (2021-09-01)

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.
por: Mahadevan, U, et al.
Publicado: (2011)

Sepsis: evolving concepts and challenges
por: R. Salomão, et al.
Publicado: (2019-04-01)